Search: WFRF:(Cilia M)
> (2022) >
Plasma neurofilamen...
-
Eratne, D.Royal Melbourne Hospital
(author)
Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives
- Article/chapterEnglish2022
Publisher, publication year, extent ...
-
2021-11-17
-
SAGE Publications,2022
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/310245
-
https://gup.ub.gu.se/publication/310245URI
-
https://doi.org/10.1177/00048674211058684DOI
-
https://lup.lub.lu.se/record/d9641489-7343-4f16-a97c-128a04377ac5URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Objective: Schizophrenia, a complex psychiatric disorder, is often associated with cognitive, neurological and neuroimaging abnormalities. The processes underlying these abnormalities, and whether a subset of people with schizophrenia have a neuroprogressive or neurodegenerative component to schizophrenia, remain largely unknown. Examining fluid biomarkers of diverse types of neuronal damage could increase our understanding of these processes, as well as potentially provide clinically useful biomarkers, for example with assisting with differentiation from progressive neurodegenerative disorders such as Alzheimer and frontotemporal dementias. Methods: This study measured plasma neurofilament light chain protein (NfL) using ultrasensitive Simoa technology, to investigate the degree of neuronal injury in a well-characterised cohort of people with treatment-resistant schizophrenia on clozapine (n = 82), compared to first-degree relatives (an at-risk group, n = 37), people with schizophrenia not treated with clozapine (n = 13), and age- and sex-matched controls (n = 59). Results: We found no differences in NfL levels between treatment-resistant schizophrenia (mean NfL, M = 6.3 pg/mL, 95% confidence interval: [5.5, 7.2]), first-degree relatives (siblings, M = 6.7 pg/mL, 95% confidence interval: [5.2, 8.2]; parents, M after adjusting for age = 6.7 pg/mL, 95% confidence interval: [4.7, 8.8]), controls (M = 5.8 pg/mL, 95% confidence interval: [5.3, 6.3]) and not treated with clozapine (M = 4.9 pg/mL, 95% confidence interval: [4.0, 5.8]). Exploratory, hypothesis-generating analyses found weak correlations in treatment-resistant schizophrenia, between NfL and clozapine levels (Spearman's r = 0.258, 95% confidence interval: [0.034, 0.457]), dyslipidaemia (r = 0.280, 95% confidence interval: [0.064, 0.470]) and a negative correlation with weight (r = -0.305, 95% confidence interval: [-0.504, -0.076]). Conclusion: Treatment-resistant schizophrenia does not appear to be associated with neuronal, particularly axonal degeneration. Further studies are warranted to investigate the utility of NfL to differentiate treatment-resistant schizophrenia from neurodegenerative disorders such as behavioural variant frontotemporal dementia, and to explore NfL in other stages of schizophrenia such as the prodome and first episode.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Janelidze, ShorenaLund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups(Swepub:lu)nkir-sje
(author)
-
Malpas, C. B.University of Melbourne,University of Calgary
(author)
-
Loi, S.Royal Melbourne Hospital
(author)
-
Walterfane, M.University of Melbourne,Royal Melbourne Hospital
(author)
-
Merritt, A.University of Melbourne
(author)
-
Diouf, I.University of Melbourne
(author)
-
Blennow, Kaj,1958Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry,Sahlgrenska University Hospital(Swepub:gu)xbleka
(author)
-
Zetterberg, Henrik,1973University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xzethe
(author)
-
Cilia, B.
(author)
-
Warman, C.University of Melbourne
(author)
-
Bousman, C.
(author)
-
Everall, I.King's College London
(author)
-
Zalesky, A.University of Melbourne
(author)
-
Jayaram, M.University of Melbourne
(author)
-
Thomas, N.University of Melbourne
(author)
-
Berkovic, S. F.University of Melbourne
(author)
-
Hansson, OskarLund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups(Swepub:lu)mphy-ohn
(author)
-
Velakoulis, D.Royal Melbourne Hospital
(author)
-
Pantelis, C.University of Melbourne
(author)
-
Santillo, AlexanderLund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups(Swepub:lu)med-ast
(author)
-
Kalincik, ThomasRoyal Melbourne Hospital
(creator_code:cre_t)
-
Royal Melbourne HospitalKlinisk minnesforskning
(creator_code:org_t)
-
MiND Study Group
Related titles
-
In:Australian and New Zealand Journal of Psychiatry: SAGE Publications56:100004-86741440-1614
Internet link
Find in a library
To the university's database
- By the author/editor
-
Eratne, D.
-
Janelidze, Shore ...
-
Malpas, C. B.
-
Loi, S.
-
Walterfane, M.
-
Merritt, A.
-
show more...
-
Diouf, I.
-
Blennow, Kaj, 19 ...
-
Zetterberg, Henr ...
-
Cilia, B.
-
Warman, C.
-
Bousman, C.
-
Everall, I.
-
Zalesky, A.
-
Jayaram, M.
-
Thomas, N.
-
Berkovic, S. F.
-
Hansson, Oskar
-
Velakoulis, D.
-
Pantelis, C.
-
Santillo, Alexan ...
-
Kalincik, Thomas
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Psychiatry
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Australian and N ...
- By the university
-
University of Gothenburg
-
Lund University